Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.35 |
| ▸ | PGR | P06401 | 5/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23479213 | 0.84 | PDE10A (0.46) | SCN10ANR3C1NR3C2PGRPRKCZ | |
| SCHEMBL23478691 | 0.83 | RAD52 (0.36) | AAK1NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL5989076 | 0.70 | DDAH1 (0.54) | SCN10AAAK1KDM4EMAPTCYP3A4 | |
| SCHEMBL23453154 | 0.69 | DAO (0.42) | MAPTNR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL19441071 | 0.69 | TDP1 (0.59) | SCN10AAAK1KDM4EMAPTCYP3A4 | |
| SCHEMBL12571647 | 0.68 | DAO (0.49) | KDM4EMAPTNR3C1NR3C2PGR | |
| SCHEMBL20993310 | 0.67 | NR3C1 (0.38) | MAPTNR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL20644584 | 0.67 | MAPT (0.38) | SCN10AKDM4EMAPTCYP3A4POLB | |
| SCHEMBL12236988 | 0.66 | SCN10A (0.48) | SCN10AAAK1KDM4EMAPTCYP3A4 | |
| SCHEMBL23840768 | 0.66 | DAO (0.46) | MAPTNR3C1NR3C2PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | SCN10A 4409/4885AAK1 1926/4885KDM4E 4019/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | SCN10A 4409/4885AAK1 1926/4885KDM4E 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.